Spotting: When to See a Doctor

What Is Spotting, Exactly?

Spotting is a small volume of vaginal bleeding, typically appearing as pink, red, or brown discharge that does not require a pad or tampon. Clinicians classify it under the broader category of abnormal uterine bleeding (AUB), using the FIGO PALM-COEIN classification system to sort causes into structural (polyp, adenomyosis, leiomyoma, malignancy) and non-structural (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, not-yet-classified) categories. The FIGO classification is described in full at the NCBI resource here.

Spotting vs. Abnormal Uterine Bleeding

The volume difference is clinically meaningful. True spotting does not soak through clothing and is often noticed only on toilet paper. When blood loss exceeds roughly 80 mL per cycle or interrupts daily activities, the clinical label shifts to heavy menstrual bleeding or AUB, and the diagnostic pathway broadens accordingly.

How Common Is Spotting?

Population data suggest intermenstrual bleeding affects approximately 25% of people with a uterus over their lifetime. A 2016 systematic review in the BMJ found that abnormal uterine bleeding accounts for up to one-third of outpatient gynecologic visits in the United States, with spotting representing the single most frequently reported variant.

Common Causes of Spotting

Spotting has a wide differential. The cause depends heavily on reproductive age, pregnancy status, contraceptive use, and the timing of bleeding within or outside the menstrual cycle.

Ovulatory (Mid-Cycle) Spotting

Mid-cycle spotting occurs around day 14 of a 28-day cycle when the pre-ovulatory estrogen surge falls sharply just before the LH surge. The brief estrogen withdrawal allows a small amount of endometrial shedding. This type is benign and self-limiting, typically lasting fewer than 3 days. No treatment is required.

Hormonal Contraception

Breakthrough bleeding is the most common cause of spotting in people using hormonal contraception. Combined oral contraceptives (COCs), the levonorgestrel IUD (Mirena, Liletta), the etonogestrel implant (Nexplanon), and depot medroxyprogesterone acetate (DMPA, Depo-Provera) all produce intermenstrual spotting during the first 3 to 6 months of use, with incidence rates of 20 to 30% for COCs and up to 50% for the etonogestrel implant in the first 90 days. FDA prescribing information for Nexplanon documents irregular bleeding as the most commonly reported adverse event leading to early removal.

Pregnancy-Related Spotting

Spotting in early pregnancy warrants same-day evaluation every time. Causes include:

• Implantation bleeding: occurs 6 to 12 days after fertilization, lasts 1 to 2 days, and is pink or brown. Benign but indistinguishable clinically from early miscarriage without measurement of serum beta-hCG.
• Threatened miscarriage: bleeding with a closed cervical os. Approximately 20% of confirmed pregnancies end in spontaneous abortion, with spotting as the first symptom in most cases. (ACOG Practice Bulletin No. 200)
• Ectopic pregnancy: classically presents with unilateral pelvic pain, spotting, and a positive pregnancy test. Ectopic pregnancy is the leading cause of first-trimester pregnancy-related death in the United States. CDC data on ectopic pregnancy confirm this remains a critical diagnostic priority.
• Placenta previa / placental abruption: second- and third-trimester causes requiring urgent obstetric care.

Cervical Causes

Cervicitis from sexually transmitted infections, particularly Chlamydia trachomatis and Neisseria gonorrhoeae, inflames the cervical epithelium and produces postcoital (after-sex) spotting. The CDC's 2021 STI Treatment Guidelines recommend NAAT testing of cervical or vaginal swabs as the preferred diagnostic approach. CDC STI Treatment Guidelines 2021

Cervical ectropion, cervical polyps, and cervical dysplasia also produce contact spotting. Any postcoital bleeding that recurs should prompt cervical inspection and Pap smear.

Structural Uterine Lesions

Endometrial polyps and submucosal fibroids (leiomyomas) are the two most frequently identified structural causes of intermenstrual spotting in reproductive-age people. A 2022 Cochrane review (CD004073) found that hysteroscopic polypectomy resolves abnormal bleeding in over 75% of cases at 12 months post-procedure.

Adenomyosis, where endometrial glands invade the myometrium, produces heavy and prolonged bleeding, often with spotting in the days before and after menstruation.

Endometrial and Cervical Cancer

These diagnoses are rare in people under 40 but must be excluded in anyone with persistent, unexplained spotting. Endometrial cancer is the most common gynecologic malignancy in the United States. The American Cancer Society estimates approximately 67,000 new endometrial cancer diagnoses annually, with postmenopausal bleeding as the presenting symptom in roughly 90% of cases.

Thyroid and Clotting Disorders

Hypothyroidism and hyperthyroidism both disrupt the hypothalamic-pituitary-ovarian axis, producing irregular cycles and spotting. Von Willebrand disease (VWD), the most common inherited bleeding disorder, is present in approximately 1% of the general population and produces heavy menstrual bleeding or spotting. NCBI: Von Willebrand Disease and Menorrhagia

Perimenopausal and Postmenopausal Spotting

The menopause transition brings erratic estrogen fluctuations that produce unpredictable spotting. Any vaginal bleeding occurring 12 or more months after the final menstrual period, the clinical definition of postmenopause, requires endometrial sampling. The Menopause Society (NAMS) 2022 Position Statement specifies that postmenopausal bleeding is abnormal until proven otherwise, regardless of hormone therapy use.

When Should You Worry About Spotting?

Most single, brief episodes of spotting in a healthy, non-pregnant reproductive-age person are benign. Certain features raise clinical urgency considerably.

Red-Flag Symptoms That Need Same-Day Contact

Call a clinician the same day if spotting is accompanied by any of the following:

• Positive or unknown pregnancy status
• Severe or one-sided pelvic pain
• Shoulder-tip pain (may indicate diaphragmatic irritation from intra-abdominal bleeding in ectopic rupture)
• Fever above 38.0 degrees C (100.4 degrees F)
• Bleeding that soaks more than one pad per hour for two or more consecutive hours
• Dizziness or syncope alongside any bleeding
• Postmenopausal bleeding of any volume

Spotting That Can Wait Up to One Week

Spotting without any red-flag features in a non-pregnant person, especially if it follows a new hormonal contraceptive or falls mid-cycle in an otherwise regular cycle, can typically be assessed at a scheduled appointment within 5 to 7 days. Keep a record of bleeding days, approximate volume, associated symptoms, and medications.

The Postmenopausal Rule

Postmenopausal bleeding has no safe "watchful waiting" threshold. A meta-analysis published in JAMA Internal Medicine found that 9% of postmenopausal women presenting with any vaginal bleeding had endometrial cancer. That single statistic justifies the standard practice of biopsy-first, reassurance-later.

How Is Spotting Diagnosed?

Diagnosis follows a structured sequence based on the patient's reproductive age and pregnancy status. The HealthRX clinical team uses the following evaluation framework, which maps onto the FIGO PALM-COEIN system and ACOG Practice Bulletin guidance.

Step 1: History and Pregnancy Test

Every evaluation begins with a urine or serum beta-hCG. Pregnancy changes the entire diagnostic tree. If positive, transvaginal ultrasound (TVUS) is the next step to localize the pregnancy and rule out ectopic implantation.

A focused history includes:

• Cycle pattern, duration of spotting, and relationship to intercourse or exertion
• Current medications (especially hormonal contraceptives, anticoagulants like warfarin or apixaban, and SSRIs, which can disrupt platelet function)
• Sexual history and STI risk factors
• Family history of bleeding disorders or gynecologic malignancy
• Menopausal status and any hormone therapy

Step 2: Physical and Pelvic Examination

Speculum exam assesses the cervix for polyps, ectropion, active bleeding, or friable tissue. Bimanual exam evaluates uterine size and adnexal tenderness. Cervical motion tenderness suggests pelvic inflammatory disease and should prompt cultures for gonorrhea and chlamydia alongside empiric antibiotic therapy per CDC guidelines.

Step 3: Laboratory Tests

Standard first-line labs include:

• Complete blood count (CBC) to assess for anemia
• Thyroid-stimulating hormone (TSH) to screen for thyroid dysfunction
• Coagulation panel (PT, aPTT, von Willebrand antigen and activity) when a bleeding disorder is suspected, particularly in adolescents with heavy bleeding since menarche
• Pap smear and cervical NAAT if due or if postcoital bleeding is present

Step 4: Imaging

Transvaginal ultrasound is the first-line imaging modality for evaluating structural causes. A 2016 ACOG Committee Opinion recommends TVUS as the initial investigation for postmenopausal bleeding; an endometrial stripe of 4 mm or less carries a less than 1% risk of endometrial cancer. Saline infusion sonohysterography (SIS) improves detection of intracavitary polyps and submucosal fibroids over standard TVUS.

Step 5: Endometrial Biopsy

Office endometrial biopsy (using a Pipelle sampler) is indicated when:

• Postmenopausal bleeding is present regardless of endometrial thickness
• The patient is 45 or older with persistent, unexplained AUB
• Risk factors for endometrial hyperplasia exist (obesity with BMI <40 kg/m2 is one such factor, though the threshold for biopsy is obesity plus anovulation, not BMI alone)
• TVUS shows endometrial thickness above 4 mm in a postmenopausal person or above 12 mm in a premenopausal person without a clear structural explanation

Pipelle sampling has a sensitivity of approximately 81% for endometrial cancer and 56% for hyperplasia, per a systematic review in the Annals of Internal Medicine.

Step 6: Hysteroscopy

Hysteroscopy remains the gold standard for direct visualization of the uterine cavity. It is recommended when office biopsy is non-diagnostic, TVUS suggests an intracavitary lesion, or symptoms persist after initial treatment.

Treatment Options for Spotting

Treatment targets the underlying cause. There is no single medication or procedure that treats "spotting" in isolation.

Hormonal Contraceptive-Related Breakthrough Bleeding

Most breakthrough bleeding resolves without intervention within the first 3 months of hormonal contraceptive use. If it persists beyond 3 months with a COC, clinicians may switch to a higher-estrogen formulation (for example, from 20 mcg to 30 mcg ethinyl estradiol) or confirm consistent pill-taking, since missed doses are the most common modifiable cause. For progestogen-only implant users, a short course of combined estrogen-progestogen (typically 20 mcg ethinyl estradiol / 100 mcg levonorgestrel for 21 days) may reduce spotting, per FSRH Clinical Guidance.

Hormonal Therapy for Structural and Ovulatory Causes

• Tranexamic acid (Lysteda): 1.3 g orally three times daily during menstruation reduces menstrual blood loss by an average of 40% and is FDA-approved for heavy menstrual bleeding. FDA label
• Norethindrone acetate (5 mg daily from days 5 to 26 of the cycle) suppresses endometrial proliferation and reduces intermenstrual bleeding in anovulatory AUB.
• Levonorgestrel IUD (Mirena, 52 mg): reduces menstrual blood loss by up to 90% at 12 months and is an ACOG first-line recommendation for AUB due to leiomyoma in people who do not desire fertility. ACOG Practice Bulletin 128

Surgical Options

• Hysteroscopic polypectomy: resolves polyp-related spotting in over 75% of cases, as noted in the Cochrane review cited above.
• Uterine fibroid embolization (UFE): minimally invasive, effective for symptomatic submucosal and intramural fibroids, with a 90% patient satisfaction rate at 5 years per data from the EMMY trial.
• Endometrial ablation: appropriate for premenopausal people with AUB who have completed childbearing. FDA-cleared thermal ablation systems achieve amenorrhea in 35 to 45% of patients and significant reduction in bleeding in up to 80% at 12 months.
• Hysterectomy: definitive treatment for AUB unresponsive to other interventions, or in confirmed endometrial cancer.

Treating Infection-Related Spotting

Cervicitis from chlamydia is treated with doxycycline 100 mg orally twice daily for 7 days per CDC 2021 STI Treatment Guidelines. Partner notification and testing are mandatory. Gonorrhea co-infection is treated with ceftriaxone 500 mg intramuscularly as a single dose (1 g if body weight exceeds 150 kg). Spotting typically resolves within 2 weeks of completing appropriate antibiotic therapy.

Managing Perimenopause-Related Spotting

Low-dose hormonal therapy, either a low-dose COC or systemic estrogen plus progestogen, stabilizes the endometrium and reduces erratic perimenopausal bleeding. The Menopause Society 2022 Hormone Therapy Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset who have bothersome symptoms, the benefits of hormone therapy outweigh the risks in the absence of contraindications." Endometrial cancer must be excluded before initiating hormonal therapy for postmenopausal bleeding.

Spotting and Hormone Therapy or GLP-1 Medications

People using testosterone therapy for gender-affirming care or for hypoactive sexual desire disorder may experience irregular spotting, particularly during the first 6 months of therapy before ovarian suppression is complete. Gynecologic surveillance, including periodic pelvic exams and cervical cancer screening, remains necessary during testosterone use. UCSF Transgender Care Guidelines recommend annual pelvic exams for transmasculine people on testosterone regardless of bleeding pattern.

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce significant weight loss. Adipose tissue is an active estrogen-producing organ. Rapid weight loss of 10 to 15% body weight, as seen in STEP-1 (N=1,961), where semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% placebo (P<0.001), may alter endometrial exposure to estrogen and trigger irregular spotting or cycle changes. People experiencing new spotting after starting a GLP-1 agonist should be evaluated to exclude structural causes before attributing the bleeding to weight-related hormonal shifts.

A Note on Tracking Spotting Before Your Appointment

Bring the following information to your appointment. It shortens the evaluation and reduces the need for repeat visits.

• Dates and duration of each spotting episode for the past 3 months
• Estimated volume (light spotting on tissue paper vs. Filling a panty liner vs. Filling a pad)
• Any associated symptoms: pain, discharge, odor, nausea, dizziness
• Full medication list, including supplements (fish oil and vitamin E both affect platelet function)
• Pregnancy test result if taken at home
• Date of last Pap smear and result

A simple symptom diary recorded in a notes app is adequate. You do not need a formal tracking application.